Statements (39)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:receptor_tyrosine_kinase
gptkb:drug |
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA 2015 |
| gptkbp:ATCCode |
gptkb:L01XE29
|
| gptkbp:brand |
gptkb:Lenvima
|
| gptkbp:CASNumber |
417716-92-8
|
| gptkbp:chemicalFormula |
C21H19ClN4O4
|
| gptkbp:combinationTherapy |
gptkb:pembrolizumab
|
| gptkbp:developedBy |
gptkb:Eisai
|
| gptkbp:eliminationHalfLife |
28 hours
|
| https://www.w3.org/2000/01/rdf-schema#label |
lenvatinib
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits FGFR
inhibits KIT inhibits PDGFRα inhibits RET inhibits VEGFR |
| gptkbp:metabolism |
liver
|
| gptkbp:molecularWeight |
426.85 g/mol
|
| gptkbp:pregnancyCategory |
D (US)
|
| gptkbp:proteinBinding |
98-99%
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:palmar-plantar_erythrodysesthesia
nausea vomiting diarrhea fatigue hypertension weight loss proteinuria decreased appetite stomatitis |
| gptkbp:usedFor |
gptkb:cancer
hepatocellular carcinoma renal cell carcinoma |
| gptkbp:bfsParent |
gptkb:Lenvima
|
| gptkbp:bfsLayer |
5
|